NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 109 filers reported holding NURIX THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $77,264 | -81.8% | 9,830 | -76.9% | 0.00% | -66.7% |
| Q2 2023 | $425,098 | +93.9% | 42,552 | +72.4% | 0.00% | +200.0% |
| Q1 2023 | $219,236 | -87.2% | 24,689 | -81.3% | 0.00% | -90.0% |
| Q3 2022 | $1,719,000 | +97.6% | 131,919 | +92.1% | 0.01% | +100.0% |
| Q2 2022 | $870,000 | +4.2% | 68,684 | +15.3% | 0.01% | -28.6% |
| Q1 2022 | $835,000 | +92.0% | 59,581 | +296.8% | 0.01% | +75.0% |
| Q4 2021 | $435,000 | +29.5% | 15,014 | +18.6% | 0.00% | 0.0% |
| Q2 2021 | $336,000 | +31.8% | 12,663 | +54.4% | 0.00% | +33.3% |
| Q1 2021 | $255,000 | – | 8,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |